Evidence map›Paper›PMID 26268657›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation.

Ryan P Sullivan, Jeffrey W Leong, Stephanie E Schneider, Aaron R Ireland, Melissa M Berrien-Elliott, Anvita Singh, Timothy Schappe, Brea A Jewell, Veronika Sexl, Todd A Fehniger

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Cancer immunology research · 2019
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Ryan P SullivanDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Jeffrey W LeongDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Stephanie E SchneiderDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Aaron R IrelandDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Melissa M Berrien-ElliottDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Anvita SinghDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Timothy SchappeDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Brea A JewellDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and.
Veronika SexlInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna 1210, Austria.
Todd A FehnigerDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and tfehnige@wustl.edu.
Washington University in St. Louis · USInstitute of Pharmacology · CZ

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1M
Viral Discovery in Rheumatoid ArthritisP30AR048335 · NIAMS · WASHINGTON UNIVERSITY · PI HSIEH, CHYI S · 2001 to 2015
$8.9M
MICRORNA REGULATION OF NK CELL DEVELOPMENT AND FUNCTIONR01AI102924 · NIAID · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2013 to 2016
$1.5M
Mechanisms underlying cytokine-induced memory-like natural killer cell differentiation and maintenance.F32CA200253 · NCI · WASHINGTON UNIVERSITY · PI ELLIOTT, MELISSA BERRIEN · 2015 to 2017
$168k
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1TR000448NCI NIH HHS F32 CA200253NCI NIH HHS P30 CA091842NCI NIH HHS P30CA091842NCI NIH HHS P30CA91842NHLBI NIH HHS T32 HL007088NIAID NIH HHS R01 AI102924NIAID NIH HHS R01AI102924NIAMS NIH HHS P30 AR048335NIAMS NIH HHS P30AR048335
6 · The paper itself

Abstract

NK cells develop in the bone marrow and complete their maturation in peripheral organs, but the molecular events controlling maturation are incompletely understood. The miR-15/16 family of microRNA regulates key cellular processes and is abundantly expressed in NK cells. In this study, we identify a critical role for miR-15/16 in the normal maturation of NK cells using a mouse model of NK-specific deletion, in which immature NK cells accumulate in the absence of miR-15/16. The transcription factor c-Myb (Myb) is expressed preferentially by immature NK cells, is a direct target of miR-15/16, and is increased in 15a/16-1 floxed knockout NK cells. Importantly, maturation of 15a/16-1 floxed knockout NK cells was rescued by Myb knockdown. Moreover, Myb overexpression in wild-type NK cells caused a defective NK cell maturation phenotype similar to deletion of miR-15/16, and Myb overexpression enforces an immature NK cell transcriptional profile. Thus, miR-15/16 regulation of Myb controls the NK cell maturation program.

Indexed as

3' Untranslated RegionsAdoptive TransferAnimalsCell DifferentiationCell LineCell ProliferationHEK293 CellsHumansInterferon-gammaKiller Cells, NaturalMiceMice, Inbred C57BLMice, KnockoutMicroRNAsProto-Oncogene Proteins c-mybRNA Interference3' Untranslated RegionsInterferon-gammaMicroRNAsMirn15 microRNA, mouseMirn16 microRNA, mouseProto-Oncogene Proteins c-mybRNA, MessengerRNA, Small Interfering

Identifiers

PMID26268657
PMCPMC4561212
OpenAlexW2151043904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.